Evidation Health announced it has closed a $10 million funding round led by Sanofi-Genzyme BioVentures, the corporate venture capital arm of Sanofi. Existing investors GE Ventures and B Capital Group also participated in the round.
The new investment will enable Evidation Health to further its capabilities in large scale behavioral analytics, health outcomes measurement, and digital biomarker development using real life patient data from hundreds of applications and devices.
“At Evidation Health, we focus on measuring behavior-driven outcomes to help our partners understand and maximize product impact in the real world,” Deborah Kilpatrick, CEO of Evidation Health said. “We are excited about the Sanofi investment, as it aligns with our creation of faster, better ways to quantify patient outcomes—which we believe will directly fuel innovation across healthcare and life sciences.”
“With the transition to value-based care, it is increasingly important for pharma companies to understand real-world behavior of individual patients and populations outside of the traditional clinical trial setting,” Bernard Davitian, Vice President and Managing Director of Sanofi-Genzyme BioVentures said. “Evidation Health’s unique capabilities in behavior analytics and integrated patient data are big enablers of this understanding. We’ve been impressed with both the Evidation team and platform, and we believe that they have the potential to transform the way pharma companies interact with patients to deliver better outcomes.”